Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Nature communications·2026

Same author

Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence.

NPJ precision oncology·2026

Same author

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer.

bioRxiv : the preprint server for biology·2026

Same author

Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2026

Same author

Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Search research articles

Related Experiment Video

Updated: Jan 18, 2026

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics.

Maria Farooq¹, Michael J Pishvaian²

¹National Cancer Institute, Bethesda, MD.

Seminars in Radiation Oncology

|September 11, 2025

Summary

Pancreatic cancer (PDAC) is a deadly disease. Molecular genetics and KRAS-targeted therapies are improving precision medicine and patient outcomes.

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Related Experiment Videos

Last Updated: Jan 18, 2026

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with poor survival rates.
PDAC is characterized by a complex tumor microenvironment and resistance to standard treatments.
Recent molecular profiling advances have significantly improved understanding of pancreatic cancer genetics.

Purpose of the Study:

To review the role of molecular genetics in advancing precision medicine for pancreatic cancer.
To highlight the impact of KRAS-targeted therapies in PDAC treatment.
To inform clinicians on optimizing treatment strategies for improved patient outcomes.

Main Methods:

Literature review of recent advances in pancreatic cancer molecular genetics.
Analysis of the impact of molecular profiling on treatment strategies.
Focus on the development and application of KRAS-targeted therapies.

Main Results:

Molecular genetics is revolutionizing the understanding and treatment of PDAC.
KRAS-targeted therapies represent a significant advancement in precision medicine for pancreatic cancer.
Optimized treatment strategies based on molecular insights are crucial for improving patient survival.

Conclusions:

Precision medicine, driven by molecular genetics, offers new hope for treating PDAC.
Targeting specific genetic mutations, like KRAS, is key to effective PDAC therapy.
Continued research and clinical application of these advances are essential for improving pancreatic cancer outcomes.